Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Updates on Clinical commissioning work programs in England

17 Dec 2019

On October 29, 2019, the NHS England updated the clinical commissioning work programs including clinical commissioning policy work program, specialized commissioning service specification work program, commissioning through evaluation work programs.

There are three types of Work Programmes:

  • Clinical commissioning policy work program;
  • Specialized commissioning service specification work program;
  • Commissioning through evaluation work programs.

Regarding clinical commissioning policy work program:

  • There are two new policy statements, which are “Abatacept as subcutaneous injection for treatment-resistant deep variant localized scleroderma “ and “Mepolizumab & benralizumab in the treatment of hypereosinophilic syndrome (HES),“ added to work program.
  • It also presents the status of work programs, paused polices, stopped policies, and rejected preliminary policy proposals, as of 15.10.2019.

Regarding specialized commissioning service specification work program:

  • It presents the status of work programs, paused service specifications, stopped service specifications, published specifications, as of 07.08.2019.

Regarding Commissioning through evaluation work programs:

  • There are two live-work program: “Rituximab for idiopathic membraneous nephropathy” and “Stereotactic Ablative Radiotherapy (SABR)”.
  • It presents the status of schemes under review, complete, declined, paused, and stopped schemes, as of 03.12.2018.

All these documents can be seen here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.